WO2019151843A1 - 락토바실러스 플란타럼 kbl396 균주 및 그 용도 - Google Patents
락토바실러스 플란타럼 kbl396 균주 및 그 용도 Download PDFInfo
- Publication number
- WO2019151843A1 WO2019151843A1 PCT/KR2019/001525 KR2019001525W WO2019151843A1 WO 2019151843 A1 WO2019151843 A1 WO 2019151843A1 KR 2019001525 W KR2019001525 W KR 2019001525W WO 2019151843 A1 WO2019151843 A1 WO 2019151843A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- strain
- lactobacillus plantarum
- kbl396
- present
- plantarum kbl396
- Prior art date
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 64
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 62
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 45
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 41
- 235000013305 food Nutrition 0.000 claims abstract description 40
- 241000894006 Bacteria Species 0.000 claims abstract description 25
- 239000000284 extract Substances 0.000 claims abstract description 24
- 239000006166 lysate Substances 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 14
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 7
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 58
- 238000011282 treatment Methods 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 229940076279 serotonin Drugs 0.000 claims description 25
- 241001465754 Metazoa Species 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000000654 additive Substances 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 230000000996 additive effect Effects 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 210000000653 nervous system Anatomy 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000024254 Delusional disease Diseases 0.000 claims description 2
- 208000014094 Dystonic disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 208000010118 dystonia Diseases 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 43
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 34
- 235000014655 lactic acid Nutrition 0.000 abstract description 17
- 239000004310 lactic acid Substances 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000035882 stress Effects 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 25
- 238000010171 animal model Methods 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 20
- 239000006041 probiotic Substances 0.000 description 20
- 235000018291 probiotics Nutrition 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 241000186660 Lactobacillus Species 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 229940039696 lactobacillus Drugs 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 230000006872 improvement Effects 0.000 description 14
- 230000000529 probiotic effect Effects 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- 101000830742 Homo sapiens Tryptophan 5-hydroxylase 1 Proteins 0.000 description 12
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 11
- 229930006000 Sucrose Natural products 0.000 description 11
- 229960004793 sucrose Drugs 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 239000002702 enteric coating Substances 0.000 description 10
- 238000009505 enteric coating Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000005720 sucrose Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000002577 cryoprotective agent Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000600 sorbitol Substances 0.000 description 8
- 235000010356 sorbitol Nutrition 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 241000186000 Bifidobacterium Species 0.000 description 7
- 230000028709 inflammatory response Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000005013 brain tissue Anatomy 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000003930 cognitive ability Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 101000851865 Homo sapiens Tryptophan 5-hydroxylase 2 Proteins 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 102100036474 Tryptophan 5-hydroxylase 2 Human genes 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 235000003969 glutathione Nutrition 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000006872 mrs medium Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- -1 salicycin Chemical compound 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 238000009004 PCR Kit Methods 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001125 extrusion Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- ZHGNHOOVYPHPNJ-UHFFFAOYSA-N Amigdalin Chemical compound FC(F)(F)C(=O)OCC1OC(OCC2OC(OC(C#N)C3=CC=CC=C3)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C2OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C(OC(=O)C(F)(F)F)C1OC(=O)C(F)(F)F ZHGNHOOVYPHPNJ-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000192001 Pediococcus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 101150058700 Tph1 gene Proteins 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 102000016679 alpha-Glucosidases Human genes 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940079919 digestives enzyme preparation Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000000695 effect on serotonin Effects 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 229950001574 riboflavin phosphate Drugs 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 235000013555 soy sauce Nutrition 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241001608472 Bifidobacterium longum Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000131482 Bifidobacterium sp. Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 241000186715 Lactobacillus alimentarius Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241001134659 Lactobacillus curvatus Species 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- 241000186610 Lactobacillus sp. Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 101001033286 Mus musculus Interleukin-1 beta Proteins 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 241000283868 Oryx Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000191998 Pediococcus acidilactici Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 229930186949 TCA Natural products 0.000 description 1
- 101150115335 TPH2 gene Proteins 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000004458 antinutrient Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 108010085318 carboxymethylcellulase Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000007267 depressive like behavior Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002322 enterochromaffin cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Definitions
- the present invention relates to a novel Lactobacillus plantarum KBL396 strain and its use, and more particularly, to a novel probiotic Lactobacillus plantarum KBL396 strain, its live cells, microorganisms, cultures, A composition containing a lysate or extract and its pharmaceutical use for improving mental health of humans.
- Probiotics refer to microorganisms with antimicrobial and enzymatic activity that help intestinal microbial balance and products produced by the microorganisms.
- probiotics are defined as live bacteria in the form of single or complex strains that are supplied to humans or animals in the form of dry cells or fermented products to improve the intestinal flora.
- Probiotics must possess the human intestine as a habitat, have non-pathogenic and non-toxic properties, and must survive on their way to the intestine. Furthermore, they must maintain viability and activity before being consumed in the delivered food, be sensitive to antibiotics used to prevent infection, and must not have antibiotic resistant plasmids. It must also be resistant to acids, enzymes and bile in the intestinal environment.
- probiotics include Bacillus sp., which has excellent ability to produce digestive enzymes (amylase, protease, lipase, cellulase, and phosphatase), Lactobacillus sp., Which produce lactic acid, and induce odor in livestock feces.
- digestive enzymes as mylase, protease, lipase, cellulase, and phosphatase
- Lactobacillus sp. which produce lactic acid, and induce odor in livestock feces.
- photosynthetic bacteria that use substances (ammonia, hydrogen sulfide, amines, etc.) to prevent odors by using metabolic processes.
- probiotics have been reported as a major therapeutic substance that can replace therapeutic agents based on existing compounds, as various health improvement effects, including improvement of intestinal health, have been reported.
- Neurological disorders include mental disorders, including anxiety, depression, schizophrenia, and cognitive impairments due to the stresses that are soaring in modern society, memory, motor skills, cognitive abilities, and other aging-related and often neurological deficits.
- Neurodegenerative diseases are increasing, characterized by the gradual loss of nerve cells of the central nervous system (CNS) and / or peripheral nervous system (PNS) accompanied by one or more degeneration or loss of sensory capacity.
- CNS central nervous system
- PNS peripheral nervous system
- Depression is a disorder that causes depression and depression as the main symptom and causes various mental and physical symptoms, leading to deterioration of daily functioning, and about 15 to 20% of the lifetime prevalence is reported to be depressive disorder.
- the cause of depression is not yet clear, but various biochemical, genetic and environmental factors, such as other mental disorders, are known to cause disease.
- the lifetime prevalence of depression is 10-25% in women, 5-12% in men, and twice as often in women.
- depression is one of the most common high frequency diseases today. Depression is a condition that exacerbates both the mind and the body. If not properly treated, it can last for several months or years, causing a loss of relationships, loss of professional productivity, and incompetence. It can lead to death, which can put a heavy burden on not only individual patients but also families and society.
- antidepressants used in clinical practice are drugs that enhance the action of monoamine neurotransmitters, which inhibit the reuptake of serotonin or norepinephrine in neurons (SSRI, SNRI, TCAs family, etc.), monoamine oxidation Like enzymes (monoamine oxidase inhibitors), they inhibit the degradation of serotonin and dopamine.
- monoamine neurotransmitters which inhibit the reuptake of serotonin or norepinephrine in neurons
- monoamine oxidation Like enzymes monoamine oxidase inhibitors
- neurodegenerative disease is a condition in which brain function is impaired by various causes, causing cognitive function to be deteriorated in general and deteriorating as a whole, resulting in significant disruption in daily life.
- the clinical loss is characterized by progressive loss of memory, cognition, reasoning, judgment, and emotional stability, leading to death.
- Alzheimer's disease is a common cause of progressive mental dysfunction (dementia) in the elderly and is considered the fourth cause of medical death in the United States.
- AD Alzheimer's disease
- cognitive and degenerative brain disorders have been found worldwide in various races and races, and have become a major public health problem.
- these diseases are estimated to affect about two to three million people in the United States alone, but they cannot be treated with current medications and are increasing worldwide as human life expectancy increases. It is important to pay attention to help.
- the present inventors consider that the health promoting effect of probiotics is not a general feature of genus and species, and corresponds to a strain-specific effect (Report of a joint) FAO / WHO working group on drafting guidelines for the evaluation of probiotics in food, London Ontario, Canada, 2002), screening a variety of probiotic strains to complete the present invention by identifying strains exhibiting excellent effects on neurological disease improvement.
- an object of the present invention is to provide a novel lactic acid bacteria.
- Another object of the present invention is to provide various food and pharmaceutical uses of the novel lactic acid bacteria.
- the present invention provides a Lactobacillus plantarum KBL396 KCTC13278BP strain.
- the present invention also provides a pharmaceutical composition comprising at least one selected from the group consisting of said strain, culture of said strain, lysate of said strain and extract of said strain.
- the present invention also provides a pharmaceutical composition for preventing or treating a neurological disease, comprising at least one selected from the group consisting of the strain, the culture of the strain, the lysate of the strain, and the extract of the strain.
- the invention also prevents or ameliorates neurological diseases, including at least one selected from the group consisting of Lactobacillus plantarum KBL396 KCTC13278BP strain, culture of the strain, lysate of the strain and extract of the strain. It provides a food composition for.
- the present invention also provides an additive for animal feed comprising at least one selected from the group consisting of Lactobacillus plantarum KBL396 KCTC13278BP strain, a culture of the strain, a lysate of the strain and an extract of the strain.
- the invention also comprises administering to a subject in need thereof one or more therapeutically effective amounts selected from the group consisting of Lactobacillus plantarum KBL396 KCTC13278BP strain, culture of said strain, lysate of said strain and extract of said strain. It provides a method of preventing or treating neurological diseases, including.
- the invention also includes at least one selected from the group consisting of Lactobacillus plantarum KBL396 KCTC13278BP strain, culture of the strain, lysate of the strain and extract of the strain for use in the prevention or treatment of neurological diseases.
- the present invention also provides a use of a composition comprising at least one selected from the group consisting of said strain, culture of said strain, lysate of said strain and extract of said strain for the manufacture of a medicament for the prevention or treatment of neurological diseases. to provide.
- TPH-1 shows the results of comparing the effects of various strains of the genus Lactobacillus and Bifidobacterium on the expression of TPH-1, the rate-regulating enzyme of the serotonin biosynthetic pathway (A), and compared with the commercially available strains of Lactobacillus. This is the result of confirming the difference between the plantarum KBL396 strain on the expression of TPH-1 (B).
- Figure 2 is a schematic (A) of the experimental instrument for the Y-MAZE test and the results of measuring the altered behavioral improvement of the administration of Lactobacillus plantarum KBL396 ( Lactobacillus plantarum KBL396) KCTC13278BP strain according to the Y-MAZE test (B).
- Figure 3 shows the results of confirming the increase in TPH-2 gene expression and serotonin (5-HT) concentration by administration of Lactobacillus plantarum KBL396 KCTC13278BP strain in the Y-MAZE test.
- FIG. 4 is a schematic diagram (B) of a cage (A) for causing stress in an animal model by social defeat and a test box for a social avoidance test.
- Figure 6 is a schematic diagram showing the tail hanging test method (A) and C57BL / 6 mice tail Lactobacillus plantarum KBL396 ( Lactobacillus plantarum KBL396) when administered the KCTC13278BP strain tail tail experiment to recover from the stress induced by social attack The result confirmed by (B).
- Figure 7 is a result of confirming the expression changes of the inflammatory cytokine IL-1ß upon administration of Lactobacillus plantarum KBL396 ( Lactobacillus plantarum KBL396) KCTC13278BP strain in the brain of the animal avoidance test (Social Avoidance Test) animal model.
- FIG. 8 shows changes in the ratio of CD4 / CD8 in spleen and changes in FOXP3 + CD25 cells in CD3 + CD4 + when Lactobacillus plantarum KBL396 KCTC13278BP strain is administered in a social avoidance test animal model. The result is.
- the Lactobacillus plantarum KBL396 strain showed a particularly excellent effect on serotonin biosynthesis and its excellent prevention, improvement and treatment for neurological diseases The effect was confirmed.
- the analysis of the 16s rDNA of the strain it was confirmed that the strain is a novel strain that is not known in the prior art.
- the present invention provides Lactobacillus plantarum KBL396 KCTC13278BP strain.
- the strain according to the invention is characterized in that it comprises a 16s rDNA sequence represented by SEQ ID NO: 1.
- the strain according to the present invention is characterized by exhibiting at least one characteristic selected from the group consisting of increased serotonin secretion, inhibition of inflammatory cytokine expression, reduction of intestinal harmful bacteria and antioxidant action.
- the strain according to the present invention as a carbon source D-ribose, D-galactose, D-glucose, D-fructose, D-mannose, mannitol, sorbitol, ⁇ -methyl-D-mannoside, ⁇ -methyl-D-glucoside , N-acetyl-glucosamine, amigdalin, arbutin, esculin, salicycin, cellobiose, maltose, lactose, melibiose, sucrose, trehalose, melezitoze and genthio Any one or more selected from the group consisting of bios can be used.
- the strain according to the present invention has at least one enzymatic activity selected from the group consisting of leucine arylamidase, valine arylamidase, ⁇ -glucosidase and ß-glucosidase.
- Lactobacillus plantarum KBL396 KCTC13278BP strain according to the present invention is safe and nontoxic in the human body and has the advantage of being easily accessible without negative recognition as a therapeutic agent, and in the improvement of neurological diseases without the risk of side effects of conventional neurological diseases. It shows an excellent effect and can be very usefully used industrially.
- the present invention provides a pharmaceutical composition comprising at least one selected from the group consisting of Lactobacillus plantarum KBL396 KCTC13278BP strain, culture of said strain, lysate of said strain and extract of said strain. to provide.
- the term “cultivation” refers to a product obtained by culturing lactic acid bacteria in a known medium, and the product may include lactic acid bacteria.
- the medium may be selected from known liquid mediums or solid mediums, and may be, for example, but not limited to, MRS liquid medium, GAM liquid medium, MRS agar medium, GAM agar medium, BL agar medium.
- fragment refers to lactic acid bacteria which have been destroyed by lactic acid bacteria by enzyme treatment, homogenization or sonication.
- extract means a product obtained by extracting lactic acid bacteria with a known extraction solvent.
- probiotic refers to the novel lactic acid bacteria of the present invention
- “killed microorganism” refers to lactic acid bacteria sterilized by heating, pressurization or drug treatment.
- the pharmaceutical composition according to the present invention has an excellent effect on the prevention or treatment of diseases of the nervous system, and shows an excellent effect as a pharmaceutical composition through the recovery of intestinal flora, antioxidant effect, immunomodulatory effect and the like.
- the pharmaceutical composition of the present invention may further comprise at least one or more pharmaceutically acceptable excipients and / or lyophilizers.
- “Pharmaceutically acceptable” refers to a physiologically acceptable and, when administered to a human, typically does not cause severe gastrointestinal disorders, dizziness, allergic reactions or the like.
- composition according to the present invention may further comprise at least one or more pharmaceutically acceptable excipients in addition to the novel lactic acid bacteria.
- Excipients that may be included in the compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose , Microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
- composition of the present invention may be formulated for oral administration or for parenteral administration by conventional methods, and when formulated, commonly used fillers, extenders, binders, wetting agents, disintegrants, surfactants, cryoprotectants And the like can be prepared.
- composition of the present invention when formulated as a solid preparation for oral administration, it includes tablets, pills, powders, granules, capsules, and the like, which solid preparations contain at least one excipient such as starch, calcium carbonate ( Calcium carbonate, Sucrose, Sucrose, Lactose, Gelatin, and the like. Further, in addition to the simple excipients may include, but are not limited to, lubricants such as magnesium stearate, talc.
- composition of the present invention when formulated as a liquid preparation for oral administration, it includes suspensions, solvents, emulsions and syrups, and other excipients such as water and liquid paraffin, which are commonly used simple diluents, such as wetting agents and sweetening agents. , Perfume, preservatives, and the like.
- composition of the present invention when formulated as a preparation for parenteral administration, it may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, suppositories.
- Non-aqueous solvents and suspensions may include, but are not limited to, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like.
- As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
- the content of the novel lactic acid bacteria and the like as an active ingredient of the pharmaceutical composition of the present invention can be adjusted in various ranges according to the specific form of the composition, purpose of use and aspects.
- the content of the active ingredient in the pharmaceutical composition according to the present invention is not significantly limited, for example, may be 0.01 to 99% by weight, specifically 0.1 to 75% by weight, more specifically 0.5 to 50% by weight based on the total weight of the composition. have.
- Lyoprotectants used in the present invention are used to preserve the probiotic formulation during lyophilization and to improve shelf-life.
- the cryoprotectant used in the present invention may include common sugars.
- the saccharide can be a mono-, di-, oligo- or polysaccharide, or a mixture of at least two or more saccharides.
- the cryoprotectant may include any one or more selected from the group consisting of sucrose, skim milk and sorbitol. More preferably, it may include sucrose, skim milk and sorbitol, and specifically, may include sucrose 2 to 20% by weight, sorbitol 2 to 20% by weight and skim milk 5 to 30% by weight relative to the total weight of the composition. Lactobacillus lyophilized by the addition of a cryoprotectant may exhibit significantly increased survival, storage stability, acid resistance and bile resistance.
- composition according to the present invention lyophilized, riboflavin (riboflavin), riboflavin phosphate (riboflavin phosphate) or its physiologically acceptable salts, glutathione (glutathion), ascorbate, glutathione ( The addition of antioxidants such as glutathion) and cysteine can further increase the survival rate of the strain during storage.
- the invention is a neurological disease comprising at least one selected from the group consisting of Lactobacillus plantarum KBL396 KCTC13278BP strain, culture of said strain, lysate of said strain and extract of said strain.
- a prophylactic or therapeutic pharmaceutical composition Provided is a prophylactic or therapeutic pharmaceutical composition.
- prevention in the present invention means any action that inhibits the symptoms or delays the progression of neurological diseases by administration of the pharmaceutical composition of the present invention.
- treatment refers to any action that improves or advantageously alters the symptoms of a neurological disease by administration of the pharmaceutical composition of the present invention.
- neurodegenerative disease includes all the pathologies derived from pathologies of the nervous system. Accordingly, the present invention aims to prevent or treat acute and / or chronic diseases associated with nerves, neuropsychiatric, mental, neurodegenerative and neurodegenerative.
- Such nervous system diseases may be mental disorders or neurodegenerative diseases.
- Non-limiting examples of mental disorders include stress tension, anxiety, depression, mood disorders, insomnia, delusional disorders, obsessive compulsive disorder, migraines, memory disorders, cognitive disorders, and attention disorders.
- non-limiting examples of neurodegenerative diseases include Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Spinocerebellar Atrophy, Tourette's Syndrome, Friedrich's syndrome. Friedrich's Ataxia, Machado-Joseph's disease, dementia, dystonia, and progressive supranuclear palsy.
- the pharmaceutical composition for preventing or treating neurological diseases according to the present invention has the advantage of being safe without toxicity in the human body and easily accessible without negative recognition as a therapeutic agent, and improving the neurological diseases without the risk of side effects of conventional neurological disease treatment agents. It shows an excellent effect on can be very useful industrially.
- the composition of the present invention induces serotonin biosynthesis and has a prophylactic, ameliorating and therapeutic effect against neurological diseases.
- the composition of the present invention has an excellent effect on improving cognitive ability.
- the composition of the present invention shows an excellent effect in the improvement of symptoms such as tension, depression, anxiety, in a stress environment.
- the composition of the present invention by controlling the inflammatory response of the nervous system shows an excellent effect on the prevention, treatment and improvement of neurological diseases.
- the composition of the present invention exhibits an excellent prophylactic, ameliorating and therapeutic effect on neurological diseases by modulating an inflammatory response.
- the composition of the present invention exhibits an excellent prophylactic, ameliorating and therapeutic effect on diseases of the nervous system by regulating inflammatory responses in the nerves and brain due to immune imbalance.
- the dosage of the pharmaceutical composition according to the present invention should be a pharmaceutically effective amount.
- “Pharmaceutically effective amount” means an amount sufficient to prevent or treat a neurological disorder at a reasonable benefit / risk ratio applicable to medical treatment. Effective dose levels can be variously selected by those skilled in the art depending on factors such as formulation method, patient's condition and weight, patient's sex, age, degree of disease, drug form, route and duration of administration, rate of excretion, response sensitivity, and the like. have. Effective amounts may vary depending on the route of treatment, the use of excipients, and the possibility of use with other agents, as will be appreciated by those skilled in the art. However, for the desired effect, the oral dosage form is generally administered to adults at 0.001 to 1000 mg / kg / day, preferably 0.01 to 100 mg / kg, per day of body weight per kilogram of body weight per day. Can be.
- the Lactobacillus plantarum KBL396 KCTC13278BP strain of the present invention can be administered at 1x10 3 CFU / kg to 1x10 11 CFU / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
- the pharmaceutical composition according to the present invention can be administered to mammals such as mice, livestock, humans, etc. through various routes.
- the pharmaceutical compositions of the present invention may be oral or parenteral (eg, applied or intravenous, subcutaneous, intraperitoneal injection), but oral administration is preferred.
- Solid preparations for oral administration may include powders, granules, tablets, capsules, soft capsules, pills, and the like.
- enteric coated enteric preparations may in particular be provided as enteric coated enteric preparations as oral unit dosage forms.
- Enteric coating includes all known types of pharmaceutically acceptable coatings that are not degraded by gastric acid so that the coating is maintained but is sufficiently degraded in the small intestine to allow the active ingredient to be released into the small intestine. do.
- the "enteric coating” of the present invention is maintained for at least 2 hours when contacting artificial gastric juice, such as HCl solution of pH 1 at 36 °C to 38 °C, preferably KH 2 PO 4 buffer solution of pH 6.8 after Refers to a coating that degrades within 30 minutes in artificial intestinal juice, such as.
- the enteric coating of the present invention is coated in one core in an amount of about 16 to 30, preferably 16 to 20 or 25 mg or less.
- the material of the enteric coating is suitably selected from known polymeric materials. Suitable polymeric materials are described in a number of known publications (L. Lachman et al., The Theory and Practice of Industrial Pharmacy, 3rd edition, 1986, pp. 365-373; H. Sucker et al., Pharmazeutician Technologie, Thieme, 1991, pp. 355-359 Hagers Handbuchder pharmazeutician fürtechnik, 4th edition, Vol. 7, pp.
- the enteric coating of the present invention can be prepared using conventional enteric coating methods that spray the enteric coating solution onto the core.
- Suitable solvents used in the enteric coating process are alcohols such as ethanol, ketones such as acetone, halogenated hydrocarbon solvents such as dichloromethane (CH 2 Cl 2 ) and mixed solvents of these solvents may be used.
- Softeners such as di-n-butylphthalate or triacetin are added to the coating solution at a ratio of 1 to about 0.05 to about 0.3 (coating material to softener). It is appropriate to carry out the spraying process continuously and it is possible to adjust the spraying amount taking into account the conditions of the coating. Spray pressure can be varied and generally satisfactory results are obtained with spray pressures of about 1 to about 1.5 bar.
- Oral liquid preparations include suspensions, solvents, emulsions, syrups, and aerosols.In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
- Formulations for parenteral administration may be formulated in the form of sterile aqueous solutions, solutions, non-aqueous solutions, suspensions, emulsions, eye drops, ophthalmic ointments, syrups, suppositories, aerosols and the like, and sterile injectables, respectively, according to conventional methods. Can be used.
- Formulations for topical administration may be anhydrous or aqueous, depending on the clinical prescription.
- the non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
- the pharmaceutical composition for preventing or treating neurological diseases according to the present invention may further contain one or more known active ingredients having a prophylactic or therapeutic effect for neurological diseases.
- the invention is a neurological disease comprising at least one selected from the group consisting of Lactobacillus plantarum KBL396 KCTC13278BP strain, culture of said strain, lysate of said strain and extract of said strain It provides a food composition for prevention or improvement.
- Food composition according to the present invention may be characterized in that the composition for food or food additives, but is not limited thereto, foods, such as the main raw material, secondary raw materials, food additives, which are effective in preventing or improving neurological diseases, It can be easily utilized as a dietary supplement or a functional beverage.
- the food means a natural product or processed product containing one or more nutrients, and preferably means a state in which it can be directly eaten through a certain processing step. It includes all additives, health foods and functional drinks.
- Foods to which the food composition according to the present invention may be added include, for example, various foods, beverages, gums, teas, vitamin complexes, functional foods, and the like.
- food includes special nutritional products (e.g., crude oil, young food, baby food, etc.), processed meat products, fish products, tofu, jelly, noodles (e.g. ramen, noodles, etc.), breads, health supplements, seasonings.
- Foods e.g. soy sauce, miso, red pepper paste, mixed soy sauce
- sauces confectionery (e.g. snacks), candy, chocolates, gums, ice creams, dairy products (e.g.
- fermented milk, cheese, etc. other processed foods
- kimchi, Pickled foods various kimchi, pickles, etc.
- beverages e.g., fruit drinks, vegetable drinks, soy milk, fermented beverages, etc.
- natural seasonings e.g. ramen soup, etc.
- the food, beverage or food additives may be prepared by a conventional manufacturing method.
- the health functional food refers to the control of biological defense rhythm, disease prevention and recovery of food groups or food compositions that have added value to the food by using physical, biochemical, or biotechnological techniques to act and express the function of the food for a specific purpose. It means a food that is designed and processed to express the body's regulation function to the living body sufficiently.
- the functional food may include food acceptable food additives, and may further include appropriate carriers, excipients and diluents commonly used in the manufacture of functional foods.
- the functional drink is a generic term for drinking to quench thirst or to enjoy a taste
- other components other than the composition containing the composition for improving or preventing the symptoms of the neurological disease as essential ingredients at the indicated ratios have special limitations. It may contain various flavors or natural carbohydrates and the like as an additional ingredient, as in normal beverages.
- foods containing food compositions for improving or preventing the symptoms of neurological diseases of the present invention foods containing various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavoring agents, colorants and Fillers (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.
- the components may be used independently or in combination.
- the amount of the composition according to the present invention may comprise from 0.001% to 100% by weight of the total food weight, preferably 1% to 99% by weight
- the amount of the composition according to the present invention may comprise from 0.001% to 100% by weight of the total food weight, preferably 1% to 99% by weight
- it may be included in a ratio of 0.001g to 10g, preferably 0.01g to 1g based on 100ml, but in the case of long-term intake for health and hygiene purposes or health control purposes It may be less than the above range, the active ingredient is not limited to the above range because it may be used in an amount above the above range because there is no problem in terms of safety.
- the food composition of the present invention may further include at least one excipient and / or lyophilizer.
- the food composition of the present invention may be added to the Lactobacillus plantarum KBL396 strain independently or in an acceptable carrier, or prepared in the form of a composition suitable for human or animal ingestion. That is, it can be used in addition to foods that do not contain other probiotic bacteria and foods that already contain some probiotic bacteria.
- other microorganisms usable with the strain of the present invention are suitable for ingestion by humans or animals and can inhibit pathogenic harmful bacteria or improve microbial balance in the mammalian intestine upon ingestion. If it has those with probiotic activity, it will not restrict
- probiotic microorganism Saccharomyces in MRS (Saccharomyces), Candida (Candida), blood teeth (Pichia) and sat rulrop cis yeast (yeast), Aspergillus (Aspergillus) containing (Torulopsis), Rhizopus Perth ( Rhizopus), myuko (Mucor), penicillin (Penicillium) fungi and Lactobacillus bacteria (Lactobacillus), Bifidobacterium (Bifidobacterium), current Kono Stock (Leuconostoc), Lactococcus (Lactococcus), Bacillus (Bacillus), such as, Streptococcus ( Streptococcus ), Gropionibacterium ( Propionibacterium ), Enterococcus , and bacteria belonging to the genus Pediococcus ( Pediococcus ).
- probiotic microorganisms include Saccharomyces cerevisiae , Bacillus coagulans , Bacillus licheniformis , Bacillus subtilis , Bifidobacterium Te Solarium bipyridinium Doom (Bifidobacterium bifidum), Bifidobacterium Infante tooth (Bifidobacterium infantis), Bifidobacterium rongeom (Bifidobacterium longum), Enterococcus passive help (Enterococcus faecium), Enterococcus faecalis (Enterococcus faecalis), Lactobacillus Lactobacillus acidophilus , Lactobacillus alimentarius , Lactobacillus casei , Lactobacillus curvatus , Lactobacillus delbruky ( Lactobacillus deltobacilli ) Lactobacillus delbruckii Lactobacillus
- a probiotic microbial mixed bacteria having excellent probiotic activity and excellent neurological disease improvement effect in the food composition of the present invention can further enhance the effect.
- carriers that may be used in the food compositions of the present invention may be extenders, high fiber additives, encapsulating agents, lipids, and the like and examples of such carriers are well known in the art.
- the Lactobacillus plantarum KBL396 of the present invention may be in lyophilized or encapsulated form or in the form of a culture suspension or dry powder.
- the present invention is for animal feed comprising one or more selected from the group consisting of Lactobacillus plantarum KBL396 KCTC13278BP strain, culture of the strain, lysate of the strain and extract of the strain Provide additives.
- the additive for animal feed of the present invention may further include at least one excipient and / or lyophilizer.
- the additive for animal feed of the present invention may be in the form of a dry or liquid formulation, and may further include other non-pathogenic microorganisms in addition to the Lactobacillus plantarum KBL396 strain.
- Microorganisms that can be added include lactose, which have physiological activity and organic degradability under anaerobic conditions, such as Bacillus subtilis , which can produce proteolytic enzymes, lipolytic enzymes and sugar converting enzymes, and bovine stomach.
- bacilli Lactobacillus strains of fungi increase the weight of cattle, such as the Aspergillus duck, showing the effect of increasing the milk production of the milk to increase the absorption of digested food party (Aspergillus oryzae) (Slyter, LLJ Animal Sci.1976, 43. 910-926) and yeasts such as Saccharomyces cerevisiae (Johnson, D. E et al. J. Anim. Sci., 1983, 56, 735-739; Williams, PEV et al, 1990, 211) and the like can be used.
- digested food party Aspergillus oryzae
- yeasts such as Saccharomyces cerevisiae (Johnson, D. E et al. J. Anim. Sci., 1983, 56, 735-739; Williams, PEV et al, 1990, 211) and the like can be used.
- the additive for animal feed of the present invention may further include one or more enzyme preparations in addition to the Lactobacillus plantarum KBL396.
- Enzyme preparation can be either dry or liquid.
- Enzyme preparations include lipases such as lipases, phytases that break down phytic acid to form phosphates and inositol phosphates, starches and Amylase, an enzyme that hydrolyzes ⁇ -1,4-glycoside bonds in glycogen, and phosphatase, cellulose, which hydrolyzes organic phosphate esters Carboxymethylcellulase that breaks down xylase, xylase that breaks down xylose, maltase and maltase that hydrolyzes maltose into two molecules of glucose Sugar-producing enzymes such as invertase, which hydrolyzes saccharose to form a glucose-fructose mixture, may be used.
- raw materials for feed include peanuts, peas, sugar beets, pulp, grain by-products, animal intestine powder, fish meal powder, etc. They may be used, and they may be used unrestricted or processed without limitation.
- the process is not necessarily limited to this, for example, a process in which a feed material is compressed to a predetermined outlet under pressure in a state of filling, and in the case of protein, an extrusion is used to denature and increase usability. It is preferable. Extrusion has the advantages of denaturing proteins and destroying antienzymatic factors through heat treatment.
- soy protein it is possible to improve the digestibility of the protein through extrusion and inactivate antinutrients such as trypsin inhibitor, one of the inhibitors of protease present in soybean, Increasing digestion can increase the nutritional value of soy protein.
- antinutrients such as trypsin inhibitor, one of the inhibitors of protease present in soybean
- the present invention provides at least one therapeutically effective amount selected from the group consisting of Lactobacillus plantarum KBL396 KCTC13278BP strain, culture of said strain, lysate of said strain and extract of said strain. It provides a method for preventing or treating a neurological disease, comprising administering to a subject in need.
- the term "therapeutically effective amount (or effective amount)” means an amount that is sufficient to deliver the desired effect but sufficient to prevent serious side effects within the scope of the medical judgment.
- the amount of microorganism to be administered into the body by the composition of the present invention can be appropriately adjusted in consideration of the route of administration and the subject of administration.
- administration is meant providing any of the pharmaceutical compositions of the invention to a subject in any suitable manner.
- the subject refers to an animal, and may be a mammal, which may typically have a beneficial effect by treatment with the novel lactic acid bacteria of the present invention.
- Preferred examples of such individuals may include primates such as humans.
- Such individuals may also include all individuals having or at risk of having an allergic disease.
- the invention is in a group consisting of Lactobacillus plantarum KBL396 KCTC13278BP strain, culture of said strain, lysate of said strain and extract of said strain for use in the prevention or treatment of neurological diseases
- compositions comprising one or more selected.
- Lactobacillus plantarum KBL396 KCTC13278BP strain for the preparation of a medicament for the prophylaxis or treatment of neurological diseases, the culture of the strain, the lysate of the strain and the extract of the strain selected from Provided is the use of a composition comprising at least one kind.
- Serotonin biosynthesis inducing ability was evaluated. Serotonin biosynthesis inducing ability was treated in each strain of RIN14B, an enterochromaffin cell cell line, and the expression of tryptophan hydroxylase-1 (TPH-1), a rate-limiting enzyme of the serotonin biosynthetic pathway, was applied to each strain. It was confirmed by observing how much is promoted by.
- Lactobacillus strains used for screening the new strains were KBL346, KBL642, KBL342, KBL649, KBL351, KBL633, KBL663, KBL621, KBL647, KBL640, KBL646, KBL639, KBL402, KBL600, KBL591, KBL538, KBL501, KBL652, KBL662, and KBL662 , KBL613, KBL544, KBL391, KBL395, KBL648, KBL497, KBL384, KBL354, KBL500, KBL362, KBL612, KBL664, KBL397, KBL545, KBL363, KBL374, KBL375, KBL385, KBL665, KBL481, KBL381, KBL851, KBL851, KBL851 , KBL365, or KBL396.
- Solace Oryx Biomedical Inc., Fremont, CA, USA
- Solace consisting of Lactobacillus plantarum PS128 single strain
- L.plantarum Quantest Vitamins Limited
- Lactobacillus plantarum 299v single strain , Kingstone, Hereford, UK
- RIN14B (ATCC CRL-2059) cell line was cultured in RPMI 1640 medium supplemented with 10% FBS, penicillin (100 ⁇ g / ml) and streptomycin (100 ⁇ g / ml) at 37 ° C and 5% CO 2 . Subcultured once. RIN14B cell lines were dispensed into 4 well plates at 4 ⁇ 10 5 cells / well in 24 well plates and cultured for 24 hours, followed by treatment with strain culture.
- the medium was removed from the RIN14B cell line dispensed in 24-well plates in Example 1-2, and then washed once with PBS (500 ⁇ l / well). Thereafter, 500 ⁇ l of the strain culture prepared in Example 1-1 was treated, or the pH of the deoxycholate in which serotonin synthesis induction was reported as a positive control was adjusted to 7.0, and then diluted in a sterilized MRS medium with a filter. After processing to 500 ⁇ l to 25 ⁇ M, and incubated for 1 hour at 37 °C, 5% CO 2 conditions, cells and supernatants were collected to confirm the expression level of TPH-1 (Tryptophan hydroxylase-1) enzyme.
- TPH-1 Tryptophan hydroxylase-1
- RNA of the cells obtained in Example 1-3 was extracted according to the manufacturer's method using Easy-spin TM Total RNA Extraction Kit (Intron). Synthesize cDNA from the extracted RNA using the High-Capacity RNA-to-cDNA TM Kit according to the manufacturer's method, and then Rotor-Gene Q (QIAGEN), Rotorgene SYBR Green PCR Kit or Quantstudio 5 (Thermofisher), Power SYBR Green Master Quantitative Real-time Polymerase Chain Reaction (qRT-PCR) was performed using Mix (Applied Biosystems).
- TPH-1 expression amount was measured using Tph-1 F and Tph1 R primers, or Tph-1A F and Tph-1A R primers as described in Table 1 below, for rat B-actin F and Rat B-actin. It was calculated as the difference in relative expression compared to the ⁇ -actin measurement measured by the R primer (delta-delata CT analysis). Primers and temperature conditions used for qRT-PCR are summarized in Table 1 and Table 2, respectively.
- FIG. 1B The results compared to commercially available Lactobacillus plantarum strains are also shown in FIG. 1B (Quantstudio 5 (Thermofisher), Power SYBR Green Master Mix (Applied Biosystems), Tph-1A F and Tph-1A R primers).
- the strain according to the present invention was confirmed that KBL396 strain is excellent in TPH-1 expression inducing ability (Q1, Lactobacillus plantarum 299v; S1, Lactobacillus plantarum PS128).
- KBL396 a strain isolated from fecal matter of a normal Korean adult female, was collected with the consent of a donor under the approval of a clinical study at Samsung Seoul Hospital (IRB No. 144-2011-07-11). It was confirmed to have induction ability.
- Example 1 the KBL396 strain showed an excellent effect on serotonin biosynthesis.
- the preclinical experiment was performed using an animal model. For this purpose, a feed containing KBL396 strain was prepared and administered to an animal model.
- Oral gavage causes significant stress in experimental animals, and such stress can affect the objectivity of the experimental results.
- Animal models are administered in the form of feed prepared by mixing the strains. The experiment was planned.
- the feed used for administration of the strain was prepared by the following method. KBL396 strains were activated by incubation for 24 hours in MRS medium, 1% inoculation in fresh MRS medium (v / v) and passaged for 24 hours. Subsequently, the culture solution was centrifuged at 6000 rpm for 4 minutes at 4 ° C. to discard the supernatant, and the pellets were released with 4 ° C. 1 ⁇ PBS. At this time, 1x PBS was added to more than 50% of the volume of the culture solution to be sufficiently released. After centrifugation under the same conditions as before, washing was repeated twice, and the pellet was released with 1 ⁇ PBS (strain concentrate).
- the powder was sterilized by radiation sterilization, and then made into a powder form, mixed with a previously prepared strain concentrate, kneaded, and formed into an appropriate size and frozen at -80 ° C for 24 hours. After lyophilization for 48-72 hours it was stored at -80 °C until use.
- the amount of KBL396 strain contained in the feed was about 1 x 10 9 CFU per gram of feed, and the control group was also mixed with PBS samples of the same mass, and prepared in the same manner as the feed prepared by mixing the strains, and at -80 ° C. Stored.
- Y-maze experiment was performed after 28 days of bacterial administration to confirm the effect of improving the cognitive ability of the KBL396 strain.
- the animal model used in the present invention was a 7-week-old C57BL / 6 mouse, and experiments were performed in eight groups of two groups, PBS control, KBL396 strain treatment group.
- Y-MAZE experiments are behavioral experiments designed to determine cognitive abilities using animal models.
- the experiment consists of three Y-shaped passages with 120 ° angles, each of which is defined as A, B, and C.
- the animals are placed in one passage for free movement for 8 minutes.
- the number and order were recorded by observation with a camera mounted on the ceiling and a computer program connected thereto. At this time, the number and order of entering each passage were recorded only when the tail was completely inserted, and the case of repeatedly entering the same branch was also recorded.
- the number and order of entering each passage were recorded only when the tail was completely inserted, and the case of repeatedly entering the same branch was also recorded.
- In case of sequentially entering three different passages (actual alteration, actual alteration), that is, in the order of ABC, CAB, BAC, etc., 1 point was given, and% alteration behavior was calculated by the following equation. It was.
- TPH-2 tryptophan hydroxylase-2
- a rate-limiting enzyme in the serotonin biosynthetic pathway of brain tissue was confirmed by the amount of mRNA of the enzyme.
- cDNA was synthesized by extracting RNA in the same manner as in Example 1-4.
- the expression level of TPH-2 was confirmed using Rotor-Gene Q (QIAGEN), Rotorgene SYBR Green PCR kit, and the following TPH-2f and TPH-2r primers in the synthesized cDNA. Analysis of the results by comparison with other experimental conditions and the amount of GAPDH gene expression was performed in the same manner as in Example 1-4.
- TPH-2f 5 'CAGTCCACGAAGATTTCGACTT 3' (SEQ ID NO: 8)
- TPH-2r 5 'GCAAGACAGCGGTAGTGTTCT 3' (SEQ ID NO: 9)
- ELISA enzyme-linked immunosorbent assay
- KBL396 strain actually increases serotonin levels in the brain, confirming that more than two times higher concentrations of serotonin (5-HT) are measured in animal models administered with KBL396 (KBL396) than animal models administered with the PBS control (PBS). It was confirmed.
- Social Avoidance Test is a behavioral test designed to assess the effects of stress using animal models.
- a social avoidance experiment was conducted according to the administration of KBL396 strain.
- the animal model used in the present invention was a seven-week-old C57BL / 6 mice, the experiment was carried out in each of eight groups of four groups of PBS control group, PBS + stress treatment group, KBL396 strain treatment group, KBL396 strain + stress treatment group.
- a total of 4 weeks (28 days) of 'feed with PBS' or 'feed with KBL396 strain' was administered and mice were exposed to stress. Even during the seven days of stress exposure, the diet continued to provide a 'feed with PBS' or a 'feed with KBL396 strain'.
- FIG. 4 is a schematic diagram (B) of a cage (A) for causing stress in an animal model by social defeat and a test box for a social avoidance test.
- C57BL / 6 mice were made to live in the same cage with a CD-1 mouse and a transparent boundary wall made of acrylic plate with a hole in the center.
- C57BL / 6 mice were transferred to large, aggressive CD-1 mice once a day and subjected to physical attack by CD-1 mice (Social defeat stress).
- C57BL / 6 mice were allowed to live for 24 hours on opposite sides with new CD-1 mice that had not been previously contacted and a transparent border.
- C57BL / 6 for 24 hours. Mice are exposed to the threat of CD-1 mice and are constantly aware of the presence of an aggressor CD-1 mouse, so that not only the physical stress during social defeat, but also the subsequent mental stress stress).
- social evasion experiments were conducted to evaluate behavioral changes due to stress exposure.
- Social avoidance experiments were carried out in the same behavioral experiment box and were conducted in two sets in total.
- the C57BL / 6 mice were placed in the center of the box and allowed to move freely for 3 minutes.
- CD-1 mice were confined in a removable enclosure and placed in the middle of one side of the behavioral experiment box to observe the behavior of C57BL / 6 mice for 3 minutes.
- the C57BL / 6 mouse exposed to the social defeat stress shows the behavior of moving away from the corner zone when the presence of the CD-1 mouse is confirmed, and the C57BL / 6 is the corner zone.
- the time to stay at was measured to determine the degree of social avoidance.
- mice administered KBL396 of the present invention was confirmed that when the social attack stress (KBL396 + STR), the degree of social avoidance is significantly improved.
- the C57BL / 6 mice that underwent social aggressive stress in Example 5 exhibit a depressive-like behavior, which is a depression mouse model already established in academia.
- a tail suspension test was conducted on C57BL / 6 mice that suffered from social attack stress in order to confirm the effect of improving depression according to the administration of the KBL396 strain.
- induction of depression through administration of strain and exposure to stress was performed similarly to the method of Example 5, and the strain was administered the same while under social attack stress.
- C57BL / 6 mice suffering from social attack stress were hung upside down by tape attached to a portion about 1 cm away from the tail end in each isolated zone, and the dead time was measured for the last 4 minutes of the total 6 minutes of the experiment.
- the floating state means the state in which the suspension is completely stopped without any movement.
- the tail suspension test results are shown in FIG. 6. As can be seen in Figure 6, compared to the depression-induced control group (PBS + STR) KBL396 administration group (KBL396 + STR), even though exposed to the same stress it was confirmed that the depression recovered to the same level as the normal control group.
- Example 7 Effect of KBL396 strain administration on the inflammatory response of the brain
- the total protein of brain tissue obtained in the animal model of Example 5 was extracted and ELISA was performed to confirm the amount of inflammatory cytokine IL-1 ⁇ .
- a 'water-soluble sample' was obtained in the same manner as in Example 4. Protein concentration measurement of 'water-soluble sample' was carried out according to the manufacturer method using the BCA Protein Assay Kit (Pierce, USA).
- a sample was prepared according to the manufacturer's method using Mouse IL-1 ⁇ ELISA kit (Sigma Aldrich) and analyzed in the same manner as in Example 4.
- the analysis results of measured IL-1 ⁇ are shown in FIG. 7.
- the concentration of IL-1 ⁇ an inflammatory cytokine
- PBS + STR the concentration of IL-1 ⁇
- KBL396 and KBL396 + STR the concentration of IL-1 ⁇ was maintained.
- Example 8 Effect of stress-induced immune imbalance regulation according to administration of KBL396 strain
- CD4 + T cells are anti-inflammatory and CD8 + T cells are responsible for promoting inflammation, and their relative decrease in CD4 / CD8 T cell ratio results in reduced immunity such as reduced infection resistance and immunoaging.
- Regulatory T cells also play a role in immune regulation to prevent excessive response of the immune system. In this way, when imbalance of immunity is regulated by T cells, an inflammatory response occurs. In particular, an inflammatory response in nerves and brain is likely to cause degenerative brain diseases such as dementia and depression. Fluorescence-activated cell sorting (FACS) was performed with spleen tissue and mesenteric lymph node cells of the mouse of Example 5 to determine how KBL396 strain affects T cells involved in immune regulation. .
- FACS Fluorescence-activated cell sorting
- Tissues were stored in ice in RPMI1640 medium containing 10% inactivated FBS at the time of sacrifice.
- the samples sampled immediately after sacrifice were filtered through a 70 ⁇ m cell strainer to obtain single cells, and then stained with trypan blue to quantify the number of living cells. Thereafter, 1x10 7 cells were transferred to 96well and a fluorescent antibody targeting the immunomarker to be identified was attached.
- the immunomarkers used here were FITC-conjugated anti-mouse CD3, PerCP-Cy5.5-conjugated anti-mouse CD4, PE-conjugated anti-mouse CD8, PE-conjugated anti-mouse FOXP3, APC-conjugated anti-mouse, respectively.
- CD25 monoclonal antibodies eBioscience. Then flow cytometry was performed through BD FACSVerse TM (BD bioscience), and immune cells were analyzed using Flowjo software (BD bioscience).
- FIG. 8 The flow cytometry results are shown in FIG. 8.
- Mice exposed to stress PBS + STR were vulnerable to inflammation due to a decrease in the proportion of CD4 / CD8 T cells in spleen tissue compared to normal mice (PBS), but significantly higher (KBL396 + STR) ratio when KBL396 strains were administered. It was confirmed that the recovery (Fig. 8A).
- the amount of regulatory T cells in mesenteric lymph nodes also decreased with stress exposure (PBS + STR), but when the KBL396 strain was administered (KBL396 + STR), it was confirmed that the mice recovered similarly (Fig. 8B). ). Therefore, it was confirmed that immune imbalance due to stress exposure can be alleviated by administration of KBL396 strain.
- KBL396 strains obtained by operating the fermenter were harvested using a centrifuge, and the remaining medium supernatant was discarded and washed with IX PBS (phosphate buffer saline) to remove the residues of the culture.
- the formulation for stable lyophilization (CPA) was treated with skim milk, sucrose and sorbitol (skim milk 11% + sucrose 4.29% + sorbitol 5.69% based on the total weight of the formulation) and lyophilization by 1X PBS treatment as a negative control group.
- Strains harvested by centrifugation were concentrated to 20 times the supernatant removed and treated with cryoprotectant (CPA). After freezing at -80 ° C for 24 hours overnight, the completed strains were subjected to two fine milling and survival rates. . The survival rate during lyophilization was confirmed by the results of CFU counts before and after freeze-drying.
- the 1X PBS treatment resulted in a survival rate of 25.8%, while the CPA treatment showed a 95% survival rate was able to confirm a significant increase in the survival rate by lyophilization.
- the inventors of the present invention patented the Lactobacillus plantarum KBL396 KCTC13278BP on May 29, 2017 to the Korea Biological Resource Center (address: 181, Korea National Institute of Biotechnology, Jeongeup-si, Jeollabuk-do 56212, Republic of Korea), accession number of KCTC13278BP was granted.
- Lactobacillus plantarum KBL396 Lactobacillus plantarum KBL396
- KCTC13278BP strain according to the present invention
- the culture of the strain, the lysate of the strain and the extract of the strain is safe without toxicity in the human body and easily accessible without negative recognition as a therapeutic agent
- it is very useful industrially to exhibit an excellent effect on the improvement of neurological diseases without the risk of side effects of conventional neurological disease treatment agents.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Abstract
Description
Claims (16)
- 락토바실러스 플란타럼 KBL396 (Lactobacillus plantarum KBL396) KCTC13278BP 균주.
- 제1항에 있어서, 락토바실러스 플란타럼 KBL396 KCTC13278BP는 서열번호 1로 표시되는 16s rDNA 서열을 포함하는 것인, 균주.
- 제1항에 있어서, 락토바실러스 플란타럼 KBL396 KCTC13278BP는 세로토닌 분비 증가, 염증성 사이토카인 발현 억제, 장내 유해균의 감소 및 항산화 작용으로 구성된 군으부터 선택되는 어느 하나 이상의 특성을 나타내는 것인, 균주.
- 락토바실러스 플란타럼 KBL396 (Lactobacillus plantarum KBL396) KCTC13278BP 균주, 상기 균주의 배양물, 상기 균주의 파쇄물 및 상기 균주의 추출물로 구성된 군에서 선택된 1종 이상을 포함하는 약학 조성물.
- 제4항에 있어서, 상기 약학 조성물은 신경계 질환 예방 또는 치료용인, 약학 조성물.
- 제5항에 있어서, 상기 신경계 질환은 정신 장애 또는 신경 퇴행성 질환인, 약학 조성물.
- 제6항에 있어서, 상기 정신 장애는 스트레스로 인한 긴장, 불안, 우울증, 기분 장애, 불면증, 망상 장애, 강박 장애, 편두통, 기억 장애, 인지 장애 및 주의력 장애로 구성된 군에서 선택된 어느 하나 이상인, 약학 조성물.
- 제6항에 있어서, 상기 신경 퇴행성 질환은 파킨슨 병, 헌팅턴 병, 알츠하이머 병, 근위축성 측삭경화증(amyotrophic lateral sclerosis), 척수소뇌성 운동실조증(Spinocerebellar Atrophy), 뚜렛 증후군(Tourette`s Syndrome), 프리드리히 보행실조(Friedrich`s Ataxia), 마차도-조셉 병(Machado-Joseph`s disease), 치매, 근육긴장이상(Dystonia) 및 진행성 핵상 마비(Progressive Supranuclear Palsy)로 구성된 군에서 선택된 어느 하나 이상인, 약학 조성물.
- 제4항에 있어서, 적어도 하나 이상의 약학적으로 허용가능한 부형제 및/또는 동결건조제를 더 포함하는 약학 조성물.
- 락토바실러스 플란타럼 KBL396 (Lactobacillus plantarum KBL396) KCTC13278BP 균주, 상기 균주의 배양물, 상기 균주의 파쇄물 및 상기 균주의 추출물로 구성된 군에서 선택된 1종 이상을 포함하는 신경계 질환 예방 또는 개선용 식품 조성물.
- 제10항에 있어서, 적어도 하나 이상의 부형제 및/또는 동결건조제를 더 포함하는 식품 조성물.
- 락토바실러스 플란타럼 KBL396 KCTC13278BP 균주, 상기 균주의 배양물, 상기 균주의 파쇄물 및 상기 균주의 추출물로 구성된 군에서 선택된 1종 이상을 포함하는 동물 사료용 첨가제.
- 제12항에 있어서, 적어도 하나 이상의 부형제 및/또는 동결건조제를 더 포함하는 동물 사료용 첨가제.
- 락토바실러스 플란타럼 KBL396 (Lactobacillus plantarum KBL396) KCTC13278BP 균주, 상기 균주의 배양물, 상기 균주의 파쇄물 및 상기 균주의 추출물로 구성된 군에서 선택된 1종 이상의 치료학적으로 유효량을 이를 필요로 하는 개체에 투여하는 단계를 포함하는 신경계 질환의 예방 또는 치료방법.
- 신경계 질환의 예방 또는 치료에 사용하기 위한 락토바실러스 플란타럼 KBL396 (Lactobacillus plantarum KBL396) KCTC13278BP 균주, 상기 균주의 배양물, 상기 균주의 파쇄물 및 상기 균주의 추출물로 구성된 군에서 선택된 1종 이상을 포함하는 조성물.
- 신경계 질환의 예방 또는 치료용의 예방 또는 치료용 약제를 제조하기 위한 락토바실러스 플란타럼 KBL396 (Lactobacillus plantarum KBL396) KCTC13278BP 균주, 상기 균주의 배양물, 상기 균주의 파쇄물 및 상기 균주의 추출물로 구성된 군에서 선택된 1종 이상을 포함하는 조성물의 용도.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112020015599-3A BR112020015599A2 (pt) | 2018-02-02 | 2019-02-07 | Cepa de lactobacillus plantarum kbl396 e uso da mesma |
RU2020126110A RU2764639C1 (ru) | 2018-02-02 | 2019-02-07 | Штамм kbl396 lactobacillus plantarum и его применение |
EP19747730.0A EP3747988A4 (en) | 2018-02-02 | 2019-02-07 | LACTOBACILLUS PLANTARUM KBL396 STRAIN AND ITS USE |
CA3089187A CA3089187A1 (en) | 2018-02-02 | 2019-02-07 | Lactobacillus plantarum kbl396 strain and use thereof |
MX2020007987A MX2020007987A (es) | 2018-02-02 | 2019-02-07 | Cepa lactobacillus plantarum kbl396 y uso de la misma. |
AU2019216129A AU2019216129B2 (en) | 2018-02-02 | 2019-02-07 | Lactobacillus plantarum KBL396 strain and use thereof |
CN201980011169.8A CN112204129B (zh) | 2018-02-02 | 2019-02-07 | 植物乳杆菌kbl396菌株及其用途 |
JP2020541769A JP6994116B2 (ja) | 2018-02-02 | 2019-02-07 | ラクトバチルスプランタルムkbl396菌株およびその用途 |
US16/962,976 US11602552B2 (en) | 2018-02-02 | 2019-02-07 | Lactobacillus plantarum KBL396 strain and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180013366 | 2018-02-02 | ||
KR10-2018-0013366 | 2018-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019151843A1 true WO2019151843A1 (ko) | 2019-08-08 |
Family
ID=67479352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/001525 WO2019151843A1 (ko) | 2018-02-02 | 2019-02-07 | 락토바실러스 플란타럼 kbl396 균주 및 그 용도 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11602552B2 (ko) |
EP (1) | EP3747988A4 (ko) |
JP (1) | JP6994116B2 (ko) |
KR (1) | KR102265538B1 (ko) |
CN (1) | CN112204129B (ko) |
AU (1) | AU2019216129B2 (ko) |
BR (1) | BR112020015599A2 (ko) |
CA (1) | CA3089187A1 (ko) |
MX (1) | MX2020007987A (ko) |
RU (1) | RU2764639C1 (ko) |
WO (1) | WO2019151843A1 (ko) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110684694A (zh) * | 2019-11-05 | 2020-01-14 | 北京科拓恒通生物技术股份有限公司 | 一株缓减精神紧张的植物乳杆菌及其应用 |
WO2021074649A3 (en) * | 2019-10-18 | 2021-07-22 | Multigerm Uk Enterprises Ltd | Methods of promoting scfa production by gut microbiota |
CN114729299A (zh) * | 2019-11-08 | 2022-07-08 | 拜奥加亚公司 | 产生血清素的细菌 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102249260B1 (ko) * | 2019-10-10 | 2021-05-10 | 경희대학교 산학협력단 | 신규 유산균 및 이의 용도 |
KR102274678B1 (ko) * | 2020-07-16 | 2021-07-12 | (주)코엔바이오 | 신규한 락토바실러스 플란타룸 아종 플란타룸 Ceb-kc-007 균주 및 이를 포함하는 항비만 효능을 가지는 조성물 |
KR102501177B1 (ko) * | 2020-09-16 | 2023-02-16 | 한국생명공학연구원 | 신규한 락토바실러스 플란타럼 균주 및 이를 이용한 패오니플로린의 생물전환방법 |
TW202241477A (zh) * | 2020-12-16 | 2022-11-01 | 日商明治股份有限公司 | 腦組織之發炎改善用組成物 |
CN112915109B (zh) * | 2021-01-21 | 2023-03-24 | 吉林省农业科学院 | 植物乳杆菌dp189在制备预防和/或治疗阿尔茨海默病药物中的应用 |
CN113073066B (zh) * | 2021-04-16 | 2022-01-04 | 段云峰 | 罗伊氏乳杆菌及其应用、组合物、药物和食品 |
KR102425902B1 (ko) * | 2021-06-15 | 2022-07-28 | 농업회사법인 유한회사 영인바이오 | 반려동물용 라면 및 이의 제조방법 |
CN113698503B (zh) * | 2021-08-16 | 2022-05-24 | 华南理工大学 | 一种植物乳杆菌中性胞外多糖及其应用 |
KR102661505B1 (ko) * | 2021-09-17 | 2024-05-07 | 주식회사 평강비아이엠 | 고염도 어류 폐기물을 이용한 사료제조방법 |
KR20230077692A (ko) | 2021-11-25 | 2023-06-01 | 국민대학교산학협력단 | 바실러스 벨레젠시스 생산 대사산물 및 락토바실러스 플란타럼 생산 대사산물을 혼합한 혼합 대사산물을 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물 |
US20230414685A1 (en) * | 2022-05-26 | 2023-12-28 | Pouda Biotech Llc | Lactobacillus plantarum pda6 having neurological effects and compositions including the same |
KR20240023749A (ko) | 2022-08-16 | 2024-02-23 | 주식회사 휴럼 | 락티플란티실러스 플란타룸 hmap12 균주 및 이를 포함하는 미세먼지에 의한 기관지염의 예방 또는 개선용 건강기능성 식품 조성물 |
KR102540559B1 (ko) | 2023-03-09 | 2023-06-13 | 주식회사 락토메이슨 | 락토바실러스 아시도필루스 lm1060 균주를 유효성분으로 포함하는 인지능력 개선용 조성물 및 이의 용도 |
CN117327631B (zh) * | 2023-11-29 | 2024-01-26 | 山东环亿生物科技有限公司 | 一种改善焦虑抑郁植物乳杆菌株10a-2及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2528610B1 (en) * | 2010-01-28 | 2013-11-13 | AB-Biotics S.A. | Probiotic composition for use in the treatment of bowel inflammation |
KR101394348B1 (ko) * | 2011-10-28 | 2014-05-13 | 대상에프앤에프 주식회사 | 대사질환 또는 염증질환 치료 및 예방 효과가 있는 락토바실러스 플란타륨 dsr920 및 이의 용도 |
US20170312232A1 (en) * | 2014-10-28 | 2017-11-02 | Medlab Ip Pty Ltd | Treatment for depression and depressive disorders |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110027348A1 (en) | 2007-08-27 | 2011-02-03 | Janos Feher | Composition and method inhibiting inflammation |
CN101302488B (zh) * | 2008-07-04 | 2010-06-30 | 中国科学院微生物研究所 | 一种生产乳酸的方法及其专用植物乳杆菌 |
CA2742476A1 (en) | 2008-11-03 | 2010-06-03 | Nestec S.A. | A nutritional composition comprising probiotics and improving sleep patterns |
JP5923238B2 (ja) * | 2010-07-07 | 2016-05-24 | アサヒグループホールディングス株式会社 | 迷走神経活性化剤 |
WO2013109635A1 (en) | 2012-01-16 | 2013-07-25 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatic diseases and disorders |
KR102129934B1 (ko) * | 2013-04-03 | 2020-07-03 | 프로비 아베 | 골다공증의 치료 또는 예방에 사용되는 프로바이오틱 스트레인 |
JP6035578B2 (ja) * | 2014-04-23 | 2016-11-30 | 國立陽明大學 | 乳酸菌、それを含む組成物及びそれらの使用 |
KR101620163B1 (ko) | 2014-05-23 | 2016-05-12 | 인제대학교 산학협력단 | 미강 추출물을 유효성분으로 포함하는 우울증 또는 인지장애의 예방 또는 치료용 조성물 |
JP6898628B2 (ja) * | 2016-06-15 | 2021-07-07 | 国立大学法人広島大学 | 神経変性疾患治療剤 |
JP6878565B2 (ja) * | 2016-07-19 | 2021-05-26 | ベネド バイオメディカル カンパニー リミテッド | 乳酸菌による大脳基底核疾患、または、チック障害を治療または予防するための薬剤 |
MY184908A (en) * | 2018-09-03 | 2021-04-30 | Aqurate Ingredients Intl M Sdn Bhd | Use of a probiotic metabolite for slowing signs of aging |
TWI731279B (zh) * | 2018-11-21 | 2021-06-21 | 葡萄王生技股份有限公司 | 發酵乳桿菌gkf3、含其之組合物及改善精神失調之用途 |
WO2020171256A1 (ko) * | 2019-02-21 | 2020-08-27 | 서울대학교산학협력단 | 클로스트리디움 디피실레(clostridium difficile) 성장 억제효과를 갖는 락토바실러스 균주 |
HRP20231084T1 (hr) * | 2019-11-08 | 2023-12-22 | Biogaia Ab | Bakterije koje proizvode serotonin |
CN112915109B (zh) * | 2021-01-21 | 2023-03-24 | 吉林省农业科学院 | 植物乳杆菌dp189在制备预防和/或治疗阿尔茨海默病药物中的应用 |
-
2019
- 2019-02-07 JP JP2020541769A patent/JP6994116B2/ja active Active
- 2019-02-07 EP EP19747730.0A patent/EP3747988A4/en active Pending
- 2019-02-07 KR KR1020190014501A patent/KR102265538B1/ko active IP Right Grant
- 2019-02-07 CA CA3089187A patent/CA3089187A1/en active Pending
- 2019-02-07 AU AU2019216129A patent/AU2019216129B2/en active Active
- 2019-02-07 WO PCT/KR2019/001525 patent/WO2019151843A1/ko unknown
- 2019-02-07 BR BR112020015599-3A patent/BR112020015599A2/pt unknown
- 2019-02-07 CN CN201980011169.8A patent/CN112204129B/zh active Active
- 2019-02-07 MX MX2020007987A patent/MX2020007987A/es unknown
- 2019-02-07 RU RU2020126110A patent/RU2764639C1/ru active
- 2019-02-07 US US16/962,976 patent/US11602552B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2528610B1 (en) * | 2010-01-28 | 2013-11-13 | AB-Biotics S.A. | Probiotic composition for use in the treatment of bowel inflammation |
KR101394348B1 (ko) * | 2011-10-28 | 2014-05-13 | 대상에프앤에프 주식회사 | 대사질환 또는 염증질환 치료 및 예방 효과가 있는 락토바실러스 플란타륨 dsr920 및 이의 용도 |
US20170312232A1 (en) * | 2014-10-28 | 2017-11-02 | Medlab Ip Pty Ltd | Treatment for depression and depressive disorders |
Non-Patent Citations (11)
Title |
---|
"Hagers Handbuchder pharmazeutischen Praxis", vol. 7, 1971, SPRINGERVERLAG, pages: 739 - 742,766-742 |
"Remington's Pharmaceutical Sciences", 1970, MACK PUBL., CO., pages: 1689 - 1691 |
BECKER ET AL., DRUG DEVELOPMENT RESEARCH, vol. 12, 1988, pages 163 - 195 |
DAVIS, D. J. ET AL.: "Lactobacillus plantarum attenuates anxiety-related behavior and protects against stress-induced dysbiosis in adult zebrafish", SCI. REP., vol. 6, 19 September 2016 (2016-09-19), pages 1 - 11, XP009511036 * |
H. SUCKER ET AL.: "Pharmazeutische Technologie", 1991, THIEME, pages: 355 - 359 |
JOHNSON, D. E ET AL., J. ANIM. SCI., vol. 56, 1983, pages 735 - 739 |
L. LACHMAN ET AL.: "The Theory and Practice of Industrial Pharmacy", 1986, pages: 365 - 373 |
REPORT OF A JOINT FAO/WHO WORKING GROUP ON DRAFTING GUIDELINES FOR THE EVALUATION OF PROBIOTICS IN FOOD, 2002 |
SLYTER, L. L., J. ANIMAL SCI., vol. 43, 1976, pages 910 - 926 |
SODHI MS ET AL., INT REV NEUROBIOL, vol. 59, 2004, pages 111 - 174 |
WALLACE, C. J. K. ET AL.: "The effects of probiotics on depressive symptoms in humans: a systematic review", ANN. GEN. PSYCHIATRY, vol. 16, no. 1, 20 February 2017 (2017-02-20), pages 1 - 10, XP055627980 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021074649A3 (en) * | 2019-10-18 | 2021-07-22 | Multigerm Uk Enterprises Ltd | Methods of promoting scfa production by gut microbiota |
CN110684694A (zh) * | 2019-11-05 | 2020-01-14 | 北京科拓恒通生物技术股份有限公司 | 一株缓减精神紧张的植物乳杆菌及其应用 |
CN114729299A (zh) * | 2019-11-08 | 2022-07-08 | 拜奥加亚公司 | 产生血清素的细菌 |
EP4253571A3 (en) * | 2019-11-08 | 2023-12-13 | Biogaia AB | Serotonin producing bacteria |
CN114729299B (zh) * | 2019-11-08 | 2024-06-18 | 拜奥加亚公司 | 产生血清素的细菌 |
Also Published As
Publication number | Publication date |
---|---|
KR102265538B1 (ko) | 2021-06-16 |
AU2019216129A1 (en) | 2020-08-06 |
CA3089187A1 (en) | 2019-08-08 |
RU2764639C1 (ru) | 2022-01-19 |
US11602552B2 (en) | 2023-03-14 |
JP6994116B2 (ja) | 2022-02-04 |
AU2019216129B2 (en) | 2022-03-17 |
KR20190094125A (ko) | 2019-08-12 |
CN112204129B (zh) | 2023-12-15 |
JP2021511804A (ja) | 2021-05-13 |
CN112204129A (zh) | 2021-01-08 |
EP3747988A1 (en) | 2020-12-09 |
BR112020015599A2 (pt) | 2021-01-05 |
EP3747988A4 (en) | 2021-11-03 |
MX2020007987A (es) | 2020-09-09 |
US20220040243A1 (en) | 2022-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019151843A1 (ko) | 락토바실러스 플란타럼 kbl396 균주 및 그 용도 | |
RU2766715C2 (ru) | Новый штамм бифидобактерии, характеризующийся различными функциями, и его применение | |
JP7088573B2 (ja) | ラクトバチルス・ガッセリーkbl697株及びその使用 | |
WO2019216662A1 (ko) | 락토바실러스 파라카제이 균주 및 그 용도 | |
US11633439B2 (en) | Lactobacillus crispatus KBL693 strain and use thereof | |
WO2021066549A1 (ko) | 락토바실러스 애시도필러스 kbl409 균주 및 그 용도 | |
WO2017047962A1 (ko) | 신규 유산균 및 퇴행성 뇌질환 또는 인지기능 장애의 예방, 개선 또는 치료용 조성물 | |
WO2019103198A1 (ko) | 락토바실러스 퍼멘텀 kbl 375 균주 및 그 용도 | |
WO2023055188A1 (ko) | 신규 프로바이오틱스 및 이의 용도 | |
WO2020045972A1 (ko) | 항비만 활성을 갖는 인체 유래 락토바실러스 퍼멘툼 엠지4231 또는 락토바실러스 퍼멘툼 엠지4244 균주 및 이를 포함하는 조성물 | |
WO2023058801A1 (ko) | 락토바실러스 애시도필러스 kbl402 또는 kbl409 균주를 포함하는 장 질환 개선, 예방 또는 치료용 조성물 | |
WO2021040086A1 (ko) | 신규한 유산균, 이를 포함하는 조성물 및 건강기능식품 | |
JP2020162479A (ja) | 目の不調を改善する組成物及びその利用 | |
WO2023153903A1 (ko) | 엔테로코커스 패칼리스, 이의 배양액 또는 이의 사균체를 유효성분으로 포함하는 지방간 예방 또는 치료용 조성물 | |
WO2022265430A1 (ko) | 대사성 질환의 예방 및 치료를 위한 락토바실러스 퍼멘텀 균주 및 자연살해세포의 병용 투여 용도 | |
KR20200143944A (ko) | 글루텐 분해능을 가지는 락토바실러스 파라카제이 glu70 균주의 사균체를 유효성분으로 함유하는 글리아딘으로 야기된 염증성 장 질환의 예방, 개선 또는 치료용 조성물 | |
KR20200099311A (ko) | 글루텐 분해능을 가지는 락토바실러스 파라카제이 glu70 균주를 유효성분으로 함유하는 글리아딘으로 야기된 염증성 장 질환의 예방, 개선 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19747730 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3089187 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020541769 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019216129 Country of ref document: AU Date of ref document: 20190207 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019747730 Country of ref document: EP Effective date: 20200902 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020015599 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112020015599 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200730 |